Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and…
Familial Patterns in Childhood- & Adult-Onset SLE
A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors.
Ultrasound Provides Insights into Immune Checkpoint Inhibitor‐Induced Inflammatory Arthritis
Ultrasound may provide unique insights into the effects of immune checkpoint inhibitors on the human body beyond the immune system. Research suggests synovitis and inflammatory tendon involvement are commonly seen in patients with immune checkpoint inhibitor-induced inflammatory arthritis.
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.
FDA Updates Boxed Warning of Benzodiazepines, Adding Risks for Abuse & Addiction
The FDA is requiring all benzodiazepines to carry an updated boxed warning that addresses the risks of misuse, abuse and addiction associated with their use.
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Hardship Exception Applications Open for Clinicians Struggling with Quality Payment Program Reporting in 2020
The Centers for Medicare & Medicaid Services have provided the opportunity to apply for exceptions for the Performance Year (PY) 2020 Quality Payment Program Merit-Based Incentive Program (MIPS) program requirements. This will help clinicians finding PY2020 MIPS federal reporting difficult due to circumstances outside their control.
UHC Announces New Copay Accumulator Policy Affecting In-Office Treatments
Editor’s note Nov. 23, 2020: As of Nov. 12, 2020, UHC has delayed implementation of the policy discussed below. See “UnitedHealthcare Delays Copay Accumulator Policy.” UnitedHealthcare (UHC) announced that, as of Jan. 1, 2021, providers will be required to report the amount their patients receive in copay assistance for office-administered treatments. UHC will then use…
Find Solutions to Navigate Telerheumatology in Your Practice
Experts weigh in on sustaining telerheumatology as a viable practice tool by sharing its history, potential and regulatory outlook post-pandemic at ACR Convergence 2020.
ACR Convergence 2020: From Clinic to Capitol Hill Session Offers Insights into Advocacy, Regulatory Issues
Attendees at the ACR Convergence session will learn about key regulatory issues affecting rheumatology and how to add their voices to strengthen the ACR’s advocacy efforts.
- « Previous Page
- 1
- …
- 176
- 177
- 178
- 179
- 180
- …
- 811
- Next Page »